OxalEurope Publications 2011/2012

  1. Beck BB, Habbig S, Dittrich K, Stippel D, Kaul I, Koerber K, Goebel H, Salido EC, Kemper M, Meyburg J, Hoppe B. Liver cell transplantation in severe infantile oxalosis – a possible bridging procedure? Nephrol Dial Transplant, 2012, epub
  2. Beck BB, Baasner A, Buescher A, Habbig S, Reintjes N, Kemper MJ, Sikora P, Mache C, Pohl M, Stahl M, Toenshoff B, Pape L, Fehrenbach H, Jacob DE, Grohe B, Wolf MT, Nürnberg G, Yigit G, Salido EC, Hoppe B.Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. Eur J Hum Genet . 2012 Jul 11. doi: 10.1038/ejhg.2012.139. [Epub ahead of print]
  3. Cellini B, Montioli R, Borri Voltattorni C. Human liver peroxisomal alanine:glyoxylate aminotransferase: characterization of the two allelic forms and their pathogenic variants. Biochim Biophys Acta 2011;1814:1577-84
  4. Cellini B, Oppici E, Paiardini A, Montioli R. Molecular insights into Primary Hyperoxaluria Pathogenesis. Frontiers in Biosciences, 2012;17:621-634
  5. Cochat P, Fargue S, Bacchetta J, Bertholet-Thomas A, Sabot JF, Harambat J. Hyperoxalurie primitive. Néphrol Thérap 2011 ; 7: 249-59
  6. Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, Fargue S, Groothoff J, Harambat J, Hoppe B, Jamieson NV, Kemper MJ, Mandrile G, Marangella M, Picca S, Rumsby G, Salido E, Straub M, van Woerden CS; OxalEurope.Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant . 2012 May;27(5):1729-36.
  7. Habbig S, Beck BB, Hoppe B. Nephrocalcinosis and urolithiasis in children. Kidney Int. 2011 Dec;80(12):1278-91. doi: 10.1038/ki.2011.336. Epub 2011 Sep 28.
  8. Harambat J, Fargue S, Bacchetta J, Acquaviva C, Cochat P. Primary hyperoxaluria. Int J Nephrol 2011 [Epub]
  9. Harambat J, van Stralen KJ, Espinosa L, Groothoff JW, Hulton SA, Cerkauskiene R, Schaefer F, Verrina E, Jager KJ, Cochat P, on behalf of the European Society for Padiatric Nephrology/European Renal Association-European Dialysis and Transplant Association (ESPN/ERA-EDTA) Registry. Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin J Am Soc Nephrol [Epub]
  10. Hoppe B, Dittlich K, Fehrenbach H, Plum G, Beck BB. Reduction of plasma oxalate levels by oral application of Oxalobacter formigenes in 2 patients with infantile oxalosis. Am J Kidney Dis. 2011 Sep;58(3):453-5. Epub 2011 Jun 25.
  11. Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, Deschênes G, Unwin R, Milliner D. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant. 2011 Nov;26(11):3609-15. Epub 2011 Apr 2.
  12. Hoppe B. The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type III (editorial comment), Nephrol Dial Transplant, 2012, in press
  13. Hoppe B. An update an primary hyperoxaluria, Nat Rev Nephrol, 2012, in press
  14. Hoppe B. The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type III. Nephrol Dial Transplant . 2012 Aug;27(8):3024-6. No abstract available.
  15. Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol . 2012 Jun 12;8(8):467-75. doi: 10.1038/nrneph.2012.113.
  16. Hueppelshaeuser R, von Unruh GE, Habbig S, Beck BB, Buderus S, Hesse A, Hoppe B. Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn's disease. Pediatr Nephrol . 2012 Jul;27(7):1103-9. Epub 2012 Feb 25.
  17. Knight J, Holmes RP, Cramer SD, Takayama T, Salido EC. Hydroxyproline Metabolism in Mouse Models of Primary Hyperoxaluria. Am J Physiol Renal Physiol. 2011 Dec 21. [Epub ahead of print]
  18. Montioli R, Fargue S, Lewin J, Zamparelli C, Danpure CJ, Borri Voltattorni C, Cellini B. The N-terminal extension is essential for the formation of the active dimeric structure of liver peroxisomal alanine:glyoxylate aminotransferase. Int J Biochem Cell Biol. 2012; in press
  19. Oppici E, Montioli R, Lorenzetto A, Bianconi S, Borri Voltattorni C, Cellini B. Biochemical analyses are instrumental in identifying the impact of mutations on holo and/or apo-forms and on the region(s) of alanine:glyoxylate aminotransferase variants associated with Primary Hyperoxaluria Type I. *Mol Gen Metab, 2012;105:132-140
  20. Pey AL, Salido E, Sanchez-Ruiz JM. Role of low native state kinetic stability and interaction of partially unfolded states with molecular chaperones in the mitochondrial protein mistargeting associated with primary hyperoxaluria. Amino Acids. 2011 Nov;41(5):1233-45. Epub 2010 Nov 20.
  21. Rathnamalala NK, Lanerolle RD, Hoppe B, Beck B.Primary hyperoxaluria presenting with early renal allograft dysfunction. Nephrology (Carlton) . 2012 May;17(4):431. doi: 10.1111/j.1440-1797.2011.01534.x. No abstract available.
  22. Robijn S, Hoppe B, Vervaet BA, D'Haese PC, Verhulst A. Hyperoxaluria: a gut-kidney axis? Kidney Int. 2011 Dec;80(11):1146-58. doi: 10.1038/ki.2011.287. Epub 2011 Aug 24.
  23. Rumsby, G: Primary Hyperoxaluria Type 2 (May 2011) in: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle, 1997-2010. Available at http://www.genetests.org
  24. Salido E, Rodriguez-Pena M, Santana A, Beattie SG, Petry H, Torres A. Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer. Mol Ther. 2011 May;19(5):870-5. Epub 2010 Nov 30.
  25. Williams E L, Bockenhauer D, Van't Hoff W G, Johri N, Laing C, Sinha MD, Unwin R, Viljoen A, Rumsby G. The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type 3. Nephrol Dial Transplant 2012 in press